Nomograms in PCa: where do we stand
- PMID: 36627379
- DOI: 10.1038/s41391-023-00642-w
Nomograms in PCa: where do we stand
References
-
- Di Stefano RF, Tucci M, Turco F, Samuelly A, Bungaro M, Pisano C, et al. Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer Prostatic Dis 2021 243. 2021;24:812–25. - DOI
-
- Roy S, Sun Y, Wallis CJD, Morgan SC, Grimes S, Malone J et al. Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer. Prostate Cancer Prostatic Dis 2022. 2022; https://doi.org/10.1038/s41391-022-00560-3 . In press.
-
- Fiori C, Checcucci E, Stura I, Amparore D, De Cillis S, Piana A et al. Development of a novel nomogram to identify the candidate to extended pelvic lymph node dissection in patients who underwent mpMRI and target biopsy only. Prostate Cancer Prostatic Dis 2022. 2022; https://doi.org/10.1038/s41391-022-00565-y . In press.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
